Liminatus Pharma Stock Soars 15.74% Amid Short Selling

On July 17, 2025, Liminatus Pharma's stock surged by 15.74% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Liminatus Pharma has no upcoming dividends, which may influence investor decisions regarding the stock. The absence of dividend payouts could be a factor in the recent price movement, as investors might be focusing on other aspects of the company's performance and potential growth opportunities.

Liminatus Pharma's stock is currently available for short selling, which could impact its price volatility. Short selling allows investors to bet against the stock, potentially driving down its price if there is significant bearish sentiment. This availability might be contributing to the recent price fluctuations as traders take positions based on their market outlook.